Anti-VEGF Therapy for Acute Thyroid Eye Disease

PHASE2RecruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

November 2, 2020

Primary Completion Date

September 30, 2025

Study Completion Date

January 1, 2027

Conditions
Thyroid Eye Disease
Interventions
DRUG

Sub-tenon injection of saline followed by a sub-tenon injection of aflibercept

The study will randomly assign a total of eight subjects into this treatment arm to receive a sub-tenon injection of saline followed by injection of 4 mg aflibercept (total volume 1.1 ml) in the worse eye. Injections will be given three times: on day 1, day 14 and day 28. Subjects will be followed until day 90.

DRUG

Sub-tenon injection of hyaluronidase (HA) followed by a sub-tenon injection of aflibercept

The study will randomly assign a total of eight subjects into this treatment arm to receive a sub-tenon injection of hyaluronidase (HA) followed by injection of 4 mg aflibercept (total volume 1.1 ml) in the worse eye. Injections will be given three times: on day 1, day 14 and day 28. Subjects will be followed until day 90.

DRUG

Sub-tenon injection of hyaluronidase (HA) alone

The study will randomly assign a total of eight subjects into this treatment arm to receive a sub-tenon injection of hyaluronidase (HA) injection alone (total volume 1.1 ml) in the worse eye. Injections will be given three times: on day 1, day 14 and day 28. Subjects will be followed until day 90.

Trial Locations (1)

02114

RECRUITING

Mass Eye and Ear, Boston

All Listed Sponsors
collaborator

Regeneron Pharmaceuticals

INDUSTRY

lead

Massachusetts Eye and Ear Infirmary

OTHER

NCT04311606 - Anti-VEGF Therapy for Acute Thyroid Eye Disease | Biotech Hunter | Biotech Hunter